Rhythm Pharmaceuticals to price initial public sale of common stock

Citigroup and Cowen were selected to be joint bookrunning managers

By Devika Patel

Knoxville, Tenn., Aug. 27 – Rhythm Pharmaceuticals, Inc. plans to conduct an initial public offering of its common stock with a greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Citigroup Global Markets Inc. and Cowen and Co. are the joint bookrunners. Canaccord Genuity, Oppenheimer & Co. and Cantor Fitzgerald & Co. are the co-managers.

Proceeds will be used for manufacturing and development, clinical trials and working capital purposes, including general operating expenses.

The biopharmaceutical company is based in Boston. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “RYTM.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.